PYOTT DAVID E I — SEC Form 4 filings
SEC reporting owner CIK 1051578. 13 Form 4 filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-05-20 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 9 legs across 3 filings — 43,720 shares, $10,531,773 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 27.
- Largest priced transaction: sale of 17,560 shares @ $220.00 ($3,863,200) in ALNYLAM PHARMACEUTICALS, INC., filed 2024-06-26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Director | 6 | — | 9 legs · 43,720 sh · $10,531,773 | 15 |
| Tarsus Pharmaceuticals, Inc. (TARS) | Director | 4 | — | — | 9 |
| PLIANT THERAPEUTICS, INC. (PLRX) | Director | 2 | — | — | 2 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | Director | 1 | — | — | 1 |
Form 4 filings — PYOTT DAVID E I
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 201 · Option exercise (M): 201 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 · Grant/award (A): 806 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 3,830 @ $0 · Sale (S): 921 @ $297.71 · Sale (S): 1,175 @ $298.91 · Sale (S): 1,222 @ $299.87 · Sale (S): 495 @ $300.72 · Sale (S): 17 @ $302.65 · +1 more | EDGAR |
| 2026-05-22 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 671 @ $0 · Grant/award (A): 1,441 (derivative) @ $0 | EDGAR |
| 2026-04-28 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 1,383 · Option exercise (M): 1,383 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 5,893 (derivative) @ $0 · Grant/award (A): 3,729 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | PLIANT THERAPEUTICS, INC. (PLRX) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-05-12 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 775 @ $0 · Grant/award (A): 1,558 (derivative) @ $0 | EDGAR |
| 2025-03-25 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 7,440 @ $88.95 · Sale (S): 7,440 @ $299 · Option exercise (M): 7,440 (derivative) @ $0 | EDGAR |
| 2024-06-26 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 17,560 @ $88.95 · Option exercise (M): 7,420 @ $70.20 · Option exercise (M): 7,470 @ $71.99 · Sale (S): 17,560 @ $220 · Sale (S): 7,420 @ $221 · Sale (S): 7,470 @ $222 · +3 more | EDGAR |
| 2024-06-17 | 4 | PLIANT THERAPEUTICS, INC. (PLRX) | Grant/award (A): 26,764 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 4,720 @ $0 | EDGAR |
| 2024-05-20 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 5,228 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1051578 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →